ARTICLE | Data Byte
Intercept’s highs and lows on the way to M&A outcome
After pair of FDA setbacks in NASH, Italian pharma Alfasigma to acquire liver disease company nearly a decade after stock peaked
September 26, 2023 9:12 PM UTC
Intercept’s long journey from Wall Street darling through a series of regulatory struggles for its NASH program is culminating in its takeout by private Italian pharma Alfasigma for $19 per share, or about $800 million.
The deal comes a few months after Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) said it would restructure in the wake of a second complete response letter for Ocaliva obeticholic acid to treat non-alcoholic steatohepatitis...
BCIQ Target Profiles